Literature DB >> 31899565

The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.

Micah Piske1, Haoxuan Zhou1, Jeong E Min1, Natt Hongdilokkul1, Lindsay A Pearce1, Fahmida Homayra1, M Eugenia Socias2,3, Gina McGowan4, Bohdan Nosyk1,5.   

Abstract

BACKGROUND AND AIMS: The 'cascade of care' framework, measuring attrition at various stages of care engagement, has been proposed to guide the public health response to the opioid overdose public health emergency in British Columbia, Canada. We estimated the cascade of care for opioid use disorder and identified factors associated with care engagement for people with opioid use disorder (PWOUD) provincially.
DESIGN: Retrospective study using a provincial-level linkage of four health administrative databases. SETTING AND PARTICIPANTS: All PWOUD in BC from 1 January 1996 to 30 November 2017. MEASUREMENTS: The eight-stage cascade of care included diagnosed PWOUD, ever on opioid agonist treatment (OAT), recently on OAT, currently on OAT and retained on OAT: ≥ 1, ≥ 3, ≥ 12 and ≥ 24 months). Health-care use, homelessness and other demographics were obtained from physician billing records, hospitalizations, and drug dispensation records. Receipt of income assistance was indicated by enrollment in Pharmacare Plan C.
FINDINGS: A total of 55 470 diagnosed PWOUD were alive at end of follow-up. As of 2017, a majority of the population (n = 39 456; 71%) received OAT during follow-up; however, only 33% (n = 18 519) were currently engaged in treatment and 16% (n = 8960) had been retained for at least 1 year. Compared with those never on OAT, those currently engaged in OAT were more likely to be aged under 45 years [adjusted odds ratio (aOR) = 1.75, 95% confidence interval (CI) = 1.64, 1.89], male (aOR = 1.72, 95% CI = 1.64, 1.82), with concurrent substance use disorders (aOR = 2.56, 95% CI = 2.44, 2.70), hepatitis C virus (HCV) (aOR = 1.22, 95% CI = 1.14, 1.33) and either homeless or receiving income-assistance (aOR = 4.35, 95% CI = 4.17, 4.55). Regular contact with the health-care system-either in out-patient or acute care settings-was common among PWOUD not engaged in OAT, regardless of time since diagnosis or treatment discontinuation.
CONCLUSIONS: People with opioid use disorder in British Columbia, Canada show high levels of out-patient care prior to diagnosis. Younger age, male sex, urban residence, lower income level and homelessness appear to be independently associated with increased opioid agonist treatment engagement.
© 2020 Society for the Study of Addiction.

Entities:  

Keywords:  Addiction; buprenorphine/naloxone; cascade of care; cohort studies; methadone; opioid agonist treatment; opioid use disorder; substance use

Mesh:

Substances:

Year:  2020        PMID: 31899565     DOI: 10.1111/add.14947

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  14 in total

1.  Cohort profile: The provincial substance use disorder cohort in British Columbia, Canada.

Authors:  Fahmida Homayra; Lindsay A Pearce; Linwei Wang; Dimitra Panagiotoglou; Tamunoibim F Sambo; Neale Smith; Rachael McKendry; Bonnie Wilson; Ronald Joe; Ken Hawkins; Rolando Barrios; Craig Mitton; Bohdan Nosyk
Journal:  Int J Epidemiol       Date:  2021-01-23       Impact factor: 7.196

2.  Opioid use disorder Cascade of care framework design: A roadmap.

Authors:  Arthur Robin Williams; Kimberly A Johnson; Cindy Parks Thomas; Sharon Reif; M Eugenia Socías; Brandy F Henry; Charles Neighbors; Adam J Gordon; Constance Horgan; Bohdan Nosyk; Karen Drexler; Noa Krawczyk; Gregg S Gonsalves; Scott E Hadland; Bradley D Stein; Marc Fishman; A Taylor Kelley; Harold A Pincus; Mark Olfson
Journal:  Subst Abus       Date:  2022       Impact factor: 3.984

3.  Opioid agonist treatment improves progression through the HIV cascade of care among people living with HIV who use unregulated opioids.

Authors:  Stephen Juwono; M-J Milloy; JinCheol Choi; Nadia Fairbairn; Seonaid Nolan; M Eugenia Socías
Journal:  AIDS       Date:  2022-05-25       Impact factor: 4.632

4.  Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota.

Authors:  Thaius Boyd; Jordan Stipek; Alex Kraft; Judge Muskrat; Kevin A Hallgren; Clinton Alexander; Brenna Greenfield
Journal:  Drug Alcohol Depend       Date:  2021-03-18       Impact factor: 4.492

5.  The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada.

Authors:  M Eugenia Socias; Cameron Grant; Kanna Hayashi; Geoff Bardwell; Mary Clare Kennedy; M-J Milloy; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2021-09-25       Impact factor: 4.492

6.  Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency.

Authors:  Marion Selfridge; Kiffer Card; Taylor Kandler; Erin Flanagan; Emily Lerhe; Ash Heaslip; Anne Nguyen; Matthew Moher; Bernie Pauly; Karen Urbanoski; Chris Fraser
Journal:  Int J Drug Policy       Date:  2022-05-04

7.  "We need to build a better bridge": findings from a multi-site qualitative analysis of opportunities for improving opioid treatment services for youth.

Authors:  Kirsten Marchand; Oonagh Fogarty; Katrina Marie Pellatt; Kayly Vig; Jordan Melnychuk; Christina Katan; Faria Khan; Roxanne Turuba; Linda Kongnetiman; Corinne Tallon; Jill Fairbank; Steve Mathias; Skye Barbic
Journal:  Harm Reduct J       Date:  2022-04-17

8.  Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.

Authors:  Farah Tahsin; Kristen A Morin; Frank Vojtesek; David C Marsh
Journal:  BMC Health Serv Res       Date:  2022-04-12       Impact factor: 2.655

9.  The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.

Authors:  Sofia R Bartlett; Stanley Wong; Amanda Yu; Margo Pearce; Julia MacIsaac; Susan Nouch; Prince Adu; James Wilton; Hasina Samji; Emilia Clementi; Hector Velasquez; Dahn Jeong; Mawuena Binka; Maria Alvarez; Jason Wong; Jane Buxton; Mel Krajden; Naveed Z Janjua
Journal:  Clin Infect Dis       Date:  2022-03-01       Impact factor: 20.999

10.  Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.

Authors:  Micah Piske; Trevor Thomson; Emanuel Krebs; Natt Hongdilokkul; Julie Bruneau; Sander Greenland; Paul Gustafson; M Ehsan Karim; Lawrence C McCandless; Malcolm Maclure; Robert W Platt; Uwe Siebert; M Eugenia Socías; Judith I Tsui; Evan Wood; Bohdan Nosyk
Journal:  BMJ Open       Date:  2020-09-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.